8 results about "In vivo tests" patented technology

An in-vivo testing device is disclosed for dynamically measuring the mechanical properties of skin. The device includes a horizontal reciprocating tensile stress-strain detection unit configured to contact the skin surface and acquire displacement and tensile force data, wherein the detection unit comprises at least two contact heads. A driving unit, equipped with a motor capable of outputting reciprocating linear motion perpendicular to the skin surface, is provided to drive the contact heads. A reversing unit converts the perpendicular reciprocating linear motion into a horizontal reciprocating tensile motion of the contact heads relative to the skin surface. The reversing unit includes at least one right-angle reversing lever connecting the driving unit and the detection unit. The disclosed device enables reliable evaluation of the dynamic viscoelastic properties of skin in a non-destructive manner, thereby providing accurate and repeatable characterization of skin biomechanics under in-vivo conditions.

This document provides methods and compositions relating to mice that express human or humanized Fcα receptors (FcαR) from the FcαR locus located in the mouse leukocyte receptor complex (LRC). In some embodiments, such mice can be used for in vivo testing of therapeutic agents containing human IgA Fc (e.g., testing of the pharmacokinetic and / or pharmacodynamic properties and dosing regimens of such therapeutic agents). This document also provides methods for using such mice, cells derived from such mice, methods for preparing such mice, and ES cells containing the same genetic modifications as such mice.

The invention belongs to the technical field of biology, and discloses application, a screening method and a medicine of Brawler's bacteria, and application of the Brawler's bacteria to preparation of anti-inflammatory drugs. Firstly, it is determined that intestinal microorganisms play an important role in resisting salmonella infection through a fecal microorganism transplantation test; secondly, screening is carried out on excrement extracts of chicken infected with salmonella, it is found that the abundance of the Brawler is extremely high, and it is further found through in-vitro tests and in-vivo tests that the Brawler can inhibit the systemic inflammatory response, caused by infection of salmonella enteritidis, of the chicken.

The application discloses a kind of pharmaceutical compositions, it includes stilben compound and pharmaceutically acceptable adjuvant;Wherein, the stilben compound is Pterostilbene or its pharmaceutically acceptable salt, the pharmaceutically acceptable adjuvant includes glucosyl tangeritin and / or glycyrrhizic acid salt.The in vitro and / or in vivo test results show that the pharmaceutical composition provided by the application has good curative effect for preventing and / or treating drug-induced liver injury;Meanwhile, it can also significantly reduce serum transaminase level, alleviate the symptoms such as liver and spleen edema, and also has good inhibitory effect on proinflammatory cytokines.The test results further show that stilben compound and pharmaceutically acceptable adjuvant (including glucosyl tangeritin and / or glycyrrhizic acid salt) combination, good safety, and easy to dissolve, release and / or absorption etc., improve the bioavailability of Pterostilbene (PTE), have synergistic effect, and have good application prospect.

A novel peptide nucleic acid (PNA) oligomer capable of forming a PNA / RNA / PNA triplex when binding to its target RNA is described. An anti-micro RNA (miRNA) capable of binding miR-155 was designed based on the novel PNA oligomer and was shown to significantly decrease miR-155 expression in vitro in lymphoma cell lines. In vivo testing in xenograft mouse models resulted in reduced miR-155 expression followed by reduced tumor growth. Methods of making and using the novel PNA oligomer for targeting other coding and noncoding RNAs are described.

The application belongs to the field of medicine, and relates to a butyrylcholinesterase selective inhibitor and a preparation method and application thereof. The application provides a brand-new butyrylcholinesterase selective inhibitor skeleton, in-vitro verification shows that part of the compounds have extremely high butyrylcholinesterase inhibitory activity and selectivity, in-vivo testing finds that a representative compound has an obvious cognitive improvement effect on an AD mouse model, and the butyrylcholinesterase selective inhibitor provided by the application has the potential to be used as a drug for preventing or treating Alzheimer's disease.

Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice. Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice.